The Targeted Solid Tumor NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ALK, BRAF, FGFR1, FGFR2, FGFR3, FGFR4, MET including MET Exon 14 skipping, NOTCH1, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, PDGFB, PDGFRA, PDGFRB, RAF1, RET, and ROS1.
Gene fusion events that deregulate protein expression or generate a chimeric protein are associated with the pathology of several cancer types. The Targeted Solid Tumor NGS Fusion Panel is intended to identify gene fusions that have been reported as oncogenic drivers in multiple solid tumors, including but not limited to NSCLC, urothelial carcinoma, cholangiocarcinoma, and thyroid carcinoma. Patients with the gene fusions may respond to select kinase inhibitors that have been approved by the FDA, including crizotinib, ceritinib, imatinib, larotrectinib, entrectinib, pemigatinib, and selpercatinib.
- FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.